Medical Cannabis Reduces Symptoms in 91% of Older Adults, Study Finds

Study Design and Patient Demographics

Researchers followed 428 patients aged 65-89 across California, Florida, and Massachusetts for six months, tracking symptom changes via monthly surveys. The cohort skewed female (62%) and had a median age of 72. Baseline conditions included chronic pain (68%), insomnia (54%), anxiety (41%), and depression (29%). Patients were cannabis-naive or hadn't used cannabis in the prior 12 months.

The study excluded patients with dementia diagnoses or active cancer treatment. All participants obtained medical cards through state-licensed physicians and purchased products from licensed dispensaries. Researchers didn't control product selection—patients chose their own formulations and dosing schedules.

Symptom Reduction Across Three Domains

At six months, 91% of participants reported clinically meaningful improvement in at least one of three domains: pain, sleep, or mood. Pain scores dropped by an average of 3.2 points on a 10-point scale. Sleep latency decreased by 28 minutes. Anxiety and depression scores improved by 31% and 27% respectively on standardized scales.

Nine percent reported no improvement. They cited side effects (5%) or lack of efficacy (4%). No serious adverse events were recorded. Common side effects included dry mouth (22%), dizziness (11%), and daytime drowsiness (8%).

Product Preferences and Dosing Patterns

Tinctures dominated usage at 58%, followed by edibles (31%) and vaporized flower (11%). Median daily THC dose was 8.4 mg; median CBD dose was 22 mg. Patients treating pain favored balanced THC:CBD ratios (1:2 to 1:3). Insomnia patients skewed toward higher-THC evening doses. Mood disorder patients used CBD-dominant products during the day and added THC at night.

By month six, 41% of participants reduced or discontinued at least one prescription medication—most commonly opioids (19%), benzodiazepines (14%), and sleep aids (12%). These reductions were patient-initiated and not protocol-mandated.

Comparison to Existing Senior-Use Data

The 91% response rate exceeds prior observational studies, which typically report 70-80% symptom improvement in older cohorts. One 2024 Israeli study of 901 patients over 65 found 78% reported benefit at 12 months. The higher rate in this study may reflect tighter inclusion criteria or the six-month endpoint, which captures early responders but not long-term dropouts.

For full background on this story, see the CannIntel topic hub on Medical Cannabis for Seniors.

Limitations and Unmeasured Variables

The study lacked a placebo arm and relied on self-reported outcomes, which limits causal inference. Researchers didn't track product cannabinoid profiles via lab testing—patients reported THC and CBD content from product labels, which vary in accuracy. Terpene content wasn't recorded. Dosing schedules were inconsistent across participants.

Demographics raise generalizability concerns. The cohort was 84% white and had higher median income than national averages for seniors. All participants had access to licensed dispensaries and could afford out-of-pocket costs, which excludes lower-income seniors in non-medical states.

Physician Attitudes and Prescribing Barriers

Forty-seven percent of participants reported their primary care physician was "neutral or unsupportive" of cannabis use. Twelve percent said their doctor explicitly discouraged it. Only 19% received dosing guidance from their certifying physician; the rest relied on dispensary staff or online research.

Physician reluctance remains a barrier to broader adoption among seniors, despite growing state-level access, the authors note. Federal Schedule I status prevents Medicare and Medicaid coverage, leaving seniors to pay $120-$240 per month on average for medical cannabis products.

What Comes Next for Senior Medical Access

The study's lead author called for randomized controlled trials with objective measures, including pain threshold testing and polysomnography for sleep outcomes. Two federally funded RCTs are underway. Results are expected in 2027 and 2028.

State medical programs continue expanding senior enrollment. Ohio's program added chronic pain and insomnia as qualifying conditions in June 2026, and New York is considering a senior-specific access pathway that would waive certification fees for patients over 70. We'll be watching enrollment trends in those states as policy changes take effect.